English Overview
Dr. Ahmed Refae, Dr. Omalkhair Abulkhair, Dr. Meteb Al-Foheidi, Dr. Abdullah Altwairgi, and Dr. Esam Murshid discuss the implications of the Overall Survival (OS) data of CDK 4 & 6 Inhibitors on patients management in clinical practice.
This Activity for
- Resident / Fellow
- Physician
- Pharmacy
What I will learn?
To discuss and share:
1. The Overall Survival data of CDK 4 & 6 inhibitors
2. HR+ HER2- MBC patients with less favorable prognosis management
3. CDK 4 & 6 inhibitors adverse event management
1. The Overall Survival data of CDK 4 & 6 inhibitors
2. HR+ HER2- MBC patients with less favorable prognosis management
3. CDK 4 & 6 inhibitors adverse event management
Speakers 5 Distinguished Speakers
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Expert Panel Discussion on Metastatic Breast Cancer (MBC) Certificate
Accreditation |
Certificate | Free |
VAT 15% Included
